Ana Carolina Vieira de Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Carolina Vieira de Lima has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anderson Felipe da Silva
Cancer Center Oncoclínicas, Brasil
1 shared publication - Andreza Alice Feitosa Ribeiro
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication - Carolina Leme de Moura Pereira
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication - Carolina Perrone Marques
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication - Fabio Pires de Souza Santos
25Oncology-Hematology Center, Hospital Israelita Albert Einstein, São Paulo, Brazil
1 shared publication - Jade Zezzi Martins Do Nascimento
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 December 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eAO0100
Molecular profile of patients with myelofibrosis: a 10-year experience
Highlights Karyotype was normal in 60% of patients and altered in 40%. The variants most often detected in the myeloid panel were: JAK2 (54%), ASXL1 (50%), TET2 (31%), and CALR (22%). The median follow-up of transplant patients was 2.4 years and the two-year overall survival was 80%. ABSTRACT Objective To analyze the karyotype test and myeloid panel with next-generation sequencing findings in patients with myelofibrosis, and to compare transplant characteristics in patients referred for bone marrow transplantation. Methods Retrospective,
- 19 December 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 21, eAO0100
Open AccessMolecular profile of patients with myelofibrosis: a 10-year experience
Highlights Karyotype was normal in 60% of patients and altered in 40%. The variants most often detected in the myeloid panel were: JAK2 (54%), ASXL1 (50%), TET2 (31%), and CALR (22%). The median follow-up of transplant patients was 2.4 years and the two-year overall survival was 80%. ABSTRACT Objective To analyze the karyotype test and myeloid panel with next-generation sequencing findings in patients with myelofibrosis, and to compare transplant characteristics in patients referred for bone marrow transplantation. Methods Retrospective,